Literature DB >> 11290881

A revised excitotoxic hypothesis of schizophrenia: therapeutic implications.

S I Deutsch1, R B Rosse, B L Schwartz, J Mastropaolo.   

Abstract

A revision of an "excitotoxic hypothesis" of schizophrenia is summarized. The hypothesis suggests that in, at least, a subtype of patients with schizophrenia, progressive excitotoxic neuronal cell death in hippocampal and cortical areas occurs via "disinhibition" of glutamatergic projections to these areas. Patients who have excitotoxic damage would be expected to have poor outcomes characterized, perhaps, by anatomic evidence of progressive neurodegeneration, pronounced negative symptoms and cognitive deficits, and profound psychosocial deterioration. Disinhibited glutamatergic activity could result from inhibition of N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission and a consequent failure to stimulate inhibitory gamma-aminobutyric acid (GABA)-ergic interneurons, and/or anatomic degeneration of inhibitory GABAergic interneurons. The result of these hypothesized mechanisms is excessive stimulation of the alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)/kainate class of glutamate receptor complexes. In turn, this excessive stimulation of AMPA/kainate receptors could lead to disruption of ionic gradients, depletion of energy reserves expended in an attempt to restore and maintain the ionic disequilibrium across neuronal membranes, generation of reactive oxygen species, and cell death from apoptotic and other mechanisms. The postulated existence of disinhibited glutamatergic neurotransmission and the subsequent cascade of excitotoxic events resulting from NMDA receptor hypofunction (NRH), anatomic degeneration of inhibitory GABAergic interneurons, or a combination of the two has suggested a diverse variety of experimental therapeutic interventions for schizophrenia. These interventions include facilitation of NMDA receptor-mediated neurotransmission, potentiation of GABAergic neurotransmission, antagonism of AMPA/kainate receptors, and "quenching" of locally generated reactive oxygen species. In fact, several of these approaches have already been pursued or are proposed as part of a systematic clinical investigation of the revised excitotoxic hypothesis of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11290881     DOI: 10.1097/00002826-200101000-00008

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  34 in total

1.  Could stress cause psychosis in individuals vulnerable to schizophrenia?

Authors:  Cheryl Corcoran; Lilianne Mujica-Parodi; Scott Yale; David Leitman; Dolores Malaspina
Journal:  CNS Spectr       Date:  2002-01       Impact factor: 3.790

2.  Modulation of sensorimotor gating in prepulse inhibition by conditional brain glycine transporter 1 deletion in mice.

Authors:  Philipp Singer; Detlev Boison; Hanns Möhler; Joram Feldon; Benjamin K Yee
Journal:  Eur Neuropsychopharmacol       Date:  2010-07-19       Impact factor: 4.600

Review 3.  Glutamate-mediated excitotoxicity in schizophrenia: a review.

Authors:  Eric Plitman; Shinichiro Nakajima; Camilo de la Fuente-Sandoval; Philip Gerretsen; M Mallar Chakravarty; Jane Kobylianskii; Jun Ku Chung; Fernando Caravaggio; Yusuke Iwata; Gary Remington; Ariel Graff-Guerrero
Journal:  Eur Neuropsychopharmacol       Date:  2014-08-01       Impact factor: 4.600

4.  GIT1 is associated with ADHD in humans and ADHD-like behaviors in mice.

Authors:  Hyejung Won; Won Mah; Eunjin Kim; Jae-Won Kim; Eun-Kyoung Hahm; Myoung-Hwan Kim; Sukhee Cho; Jeongjin Kim; Hyeran Jang; Soo-Churl Cho; Boong-Nyun Kim; Min-Sup Shin; Jinsoo Seo; Jaeseung Jeong; Se-Young Choi; Daesoo Kim; Changwon Kang; Eunjoon Kim
Journal:  Nat Med       Date:  2011-04-17       Impact factor: 53.440

Review 5.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

6.  NR1 knockdown reveals CA1 injury during a developmental period of high seizure susceptibility despite reduced seizure activity.

Authors:  J Kaur; R Keesey; B Magrys; H Liu; L K Friedman
Journal:  Neuromolecular Med       Date:  2007-08-14       Impact factor: 3.843

Review 7.  Nicotine and nicotinic system in hypoglutamatergic models of schizophrenia.

Authors:  Yousef Tizabi
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

8.  T cell deficiency leads to cognitive dysfunction: implications for therapeutic vaccination for schizophrenia and other psychiatric conditions.

Authors:  Jonathan Kipnis; Hagit Cohen; Michal Cardon; Yaniv Ziv; Michal Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-12       Impact factor: 11.205

9.  Altered striatal functional connectivity in subjects with an at-risk mental state for psychosis.

Authors:  Orwa Dandash; Alex Fornito; Jimmy Lee; Richard S E Keefe; Michael W L Chee; R Alison Adcock; Christos Pantelis; Stephen J Wood; Ben J Harrison
Journal:  Schizophr Bull       Date:  2013-07-16       Impact factor: 9.306

10.  Glutamatergic deficits and parvalbumin-containing inhibitory neurons in the prefrontal cortex in schizophrenia.

Authors:  B K Y Bitanihirwe; M P Lim; J F Kelley; T Kaneko; T U W Woo
Journal:  BMC Psychiatry       Date:  2009-11-16       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.